SCHEMBL26212933

SCHEMBL26212933

CC(C)(C)c1ccc(S(=O)(=O)NCCCl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 2/20 0.60
TP53 P04637 1/20 0.57
ALOX15 P16050 1/20 0.52
HDAC3 O15379 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
UQCRB P14927 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
HSD17B2 P37059 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14299193 0.84 CA1 (0.64) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL28078128 0.83 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL4235116 0.83 CYP3A4 (0.64) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL2054662 0.83 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL26212894 0.83 CA1 (0.58) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL23054307 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2HTTLMNATP53
Hydrochloric Acid SCHEMBL27202581 0.81 CYP3A4 (0.62) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL1504601 0.80 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2HTTLMNAALOX15
SCHEMBL6498413 0.80 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2HTTLMNATP53
SCHEMBL12169385 0.80 TSHR (0.67) ALDH1A1SMN1; SMN2HTTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4175718-B1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIV CLAUDE BERNARD LYON (FR) 2024-10-02 EP disclosed
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 ALDH1A1 995/4885SMN1; SMN2 4836/4885HTT 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.